Media coverage about G1 THERAPEUTICS (NASDAQ:GTHX) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. G1 THERAPEUTICS earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.9296744131878 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of G1 THERAPEUTICS (NASDAQ:GTHX) opened at 24.89 on Friday. The firm has a 50-day moving average price of $18.63 and a 200-day moving average price of $17.51. The stock’s market cap is $704.01 million. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67.

G1 THERAPEUTICS (NASDAQ:GTHX) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.48). Equities analysts forecast that G1 THERAPEUTICS will post ($2.92) EPS for the current year.

A number of brokerages have commented on GTHX. Cowen and Company began coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They issued an “outperform” rating and a $31.00 price target for the company. Needham & Company LLC began coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They issued a “buy” rating and a $34.00 price target for the company. Wedbush began coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They issued an “outperform” rating and a $31.00 price target for the company. Finally, J P Morgan Chase & Co began coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They issued an “overweight” rating and a $23.00 price target for the company.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect G1 THERAPEUTICS (GTHX) Share Price” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/01/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-g1-therapeutics-gthx-share-price.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.